الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 132 |  |  |
| | | from | 132 | | |
Abstract
Cross-linking is a natural phenomenon in cornea with aging in an enzymatic or nonenzymatic pattern which will be accelerated in diabetes in a nonenzymatic pattern. This suggests that artificial cross-linking may have similar effects to enhance tissue stiffness. Riboflavin/UVA corneal collagen cross-linking has been applied in the treatment of keratoconus in clinical practice in past decades. Besides its original application on keratoconus, CXL has been applied onto keratectasia and keratitis.
However, the mechanism underlying the therapeutic effect of CXL on corneal related disease is still not fully explored, and the efficacy of its clinical application needs to be further evaluated.
Medical treatment for infectious keratitis is the standard of care. Surgical intervention may be needed if medical treatment fails or complications arise.
Since first applied in treatment of infective keratitis in 2000, numerous case reports and case series support the use of CXL in bacterial keratitis, with more variable outcomes in cases of fungal, Acanthamoeba, and viral keratitis.